BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HADLIMA (adalimumab-bwwd) by Samsung Bioepis is tumor necrosis factor receptor blocking activity [moa]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HADLIMA (adalimumab-BWWD) is a biosimilar monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is indicated for TNF-mediated inflammatory diseases, though specific approved indications are not listed in available data. The product represents Samsung Bioepis's entry into the competitive TNF-inhibitor biosimilar market.
$0.014BPart D
PeakHADLIMA is at peak maturity as a biosimilar in a saturated TNF-inhibitor market, suggesting stable but competitive team sizing focused on market defense and managed care access.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HADLIMA offers limited career growth opportunities given its peak lifecycle stage and highly competitive biosimilar market. Roles focus on defending market share, negotiating payer agreements, and optimizing existing commercial infrastructure rather than driving innovation or expansion.
Brand Manager
Worked on HADLIMA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.